Nominations for the 2014 award are now closed.
The Award and Lecture
The AACR and its Chemistry in Cancer Research Working Group established this award in 2007 to recognize the importance of chemistry to advancements in cancer research. The award will be given for outstanding, novel and significant chemistry research, which has led to important contributions to the fields of basic cancer research, translational cancer research, cancer diagnosis, the prevention of cancer or the treatment of patients with cancer. Such research may include, but is not limited to, drug discovery and design; structural biology; proteomics, metabolomics and biological mass spectrometry; chemical aspects of carcinogenesis; imaging agents and radiotherapeutics; and chemical biology.
The winner of the Eighth Annual AACR Award for Outstanding Achievement in Chemistry in Cancer Research will give a 50-minute lecture during the AACR Annual Meeting 2014 in San Diego, Calif., USA (April 5-9, 2014), receive a commemorative award, a $10,000 honorarium, and receive support for the winner and a guest to attend the Annual Meeting.
- Candidacy is open to all researchers who are affiliated with any institution involved in cancer research, cancer medicine, or cancer-related biomedical science anywhere in the world. Such institutions include those in academia, industry or government.
- The award will be presented to an individual investigator. Two or more individuals may be selected to share the award when their investigations are closely related in subject matter and have resulted in work worthy of an award.
- Institutions or organizations are not eligible for the award.
- Selection of the award winner will be made on the outstanding quality, novelty and significance of the candidates' chemistry research and its important contributions to cancer research. No regard will be given to race, gender, nationality, geographic location or religious or political views.
- Prior recipients of the AACR-Bruce F. Cain Memorial Award are not eligible to be nominated for research previously recognized by the Cain Award.
Nominations are closed.
Nominations may be made by any scientist, whether an AACR member or nonmember, who is now or has been affiliated with any institution involved in cancer research, cancer medicine or cancer-related biomedical science. Candidates may not nominate themselves.
Nomination Procedure and Instructions
Nominations must be emailed to email@example.com by 4:00 p.m. United States Eastern Time on Thursday, October 3, 2013. Paper nominations will not be accepted.
Nomination Materials to be submitted are:
1) Nomination Letter Must:
- be addressed to the Selection Committee;
- be written in English; and not exceed 1,000 words;
- specify the AACR Award for which the candidate is being nominated;
- contain a concise description of the candidate's outstanding, novel, and significant chemistry research, which has led to important contributions to the fields of basic cancer research; translational cancer research; cancer diagnosis; the prevention of cancer; or the treatment of patients with cancer, with the publications supporting these accomplishments directly referenced within the letter;
- contain a concise description of the impact of these accomplishments on the field; and
- be signed by the nominator(s).
2) Candidate's CV. The candidate's curriculum vitae in English, including a complete list of the candidate's publications.
3) Summary Statement. A statement, no more than 50 words, summarizing the candidate's research accomplishments for which he or she is being nominated.
Full nomination instructions and program guidelines are available at the following link:
Nominators are asked to maintain the confidentiality of the nomination process and to refrain from informing the candidate about the nomination.
There is no restriction on the number of candidates who may be nominated by any individual scientist. There is no restriction on the number of nominators who may write nomination letters or who may sign a single nomination letter on behalf of a candidate.
If two or more candidates are nominated to share the award, a curriculum vitae and full publication history for all candidates must be submitted along with a combined letter of recommendation that fulfills the above criteria and clearly outlines how the work of the individuals is related and is worthy of the award.
Candidates will be considered by a Selection Committee of international cancer leaders appointed by the president of the AACR. The committee will consider all nominations as they have been submitted; the committee may not combine submitted nominations, add a new candidate to a submitted nomination, or otherwise make alterations to the submitted nominations. After careful deliberations by the committee, its recommendations will be forwarded to the Executive Committee of the AACR for final consideration and decision. Selection of the award winner will be made on the basis of the candidate's outstanding, novel and significant chemistry research related to cancer. No regard will be given to age, race, gender, nationality, geographic location or religious or political views.
Generously supported by Ash Stevens, Inc.
Linda Stokes, Program Associate
American Association for Cancer Research
17th Floor, 615 Chestnut Street
Philadelphia, PA 19106-4404
Seventh Annual Award Recipient
Alexander Levitzki, Ph.D., M.Sc.
Wolfson Family Professor Emeritus of Biochemistry
Unit of Cellular Signaling
Department of Biological Chemistry
The Hebrew University of Jerusalem
Dr. Levitzki delivered his award lecture titled Eradicating Tumors by Targeting Non-Viral Vectors Carrying PolylC
, at the AACR Annual Meeting 2013 in Washington, D.C. The award ceremony and lecture was held on Tuesday, April 9, 2013. Visit the AACR Annual Meeting 2013
page to learn more about the Annual Meeting.
Dr. Alexander Levitzki is honored for his pioneering signal transduction therapy and for developing tyrosine kinase inhibitors as effective agents against cancer and a range of other diseases.
Dr. Levitzki pioneered the development of tyrosine phosphorylation inhibitors (tyrphostins) against a wide spectrum of protein tyrosine kinases. In 1988, he conducted a systematic screening of low molecular weight protein tyrosine kinase inhibitors synthesized by his team, and identified the most potent compounds that inhibited EGFR and the EGF-dependent proliferation of cancer cells. He demonstrated the activity and specificity of these inhibitors at a time when most researchers believed they could not be developed for clinical applications, since such an inhibitor may have extensive homology to other members of the protein kinase “super-family” and, therefore, lack specificity. Dr. Levitzki subsequently synthesized inhibitors that showed remarkable specificity to several other kinase targets including HER-2, the Bcr-Abl fusion protein, the PDGF receptor, the VEGF receptor and Jak-2.
Dr. Levitzki’s concept of targeted cancer therapy using protein tyrosine kinase inhibitors is extensively used by the pharmaceutical industry worldwide to develop anticancer drugs. His studies formed the basis for the development of drugs like imatinib, Tarceva, and lapatinib, used for the treatment of patients with chronic myeloid leukemia, lung cancer and breast cancer, respectively. Currently there are 15 tyrosine kinase inhibitors in the clinic and many at various stages of the U.S. Food and Drug Administration’s approval process. His method of large-scale screening of synthetic compounds tested against a large spectrum of protein kinases for specificity, followed by systematic testing in cell lines and animal studies, became the standard procedure in most of the laboratories working in that field.
Dr. Levitzki also laid the foundation for establishing the field of medicinal chemistry in the design of tyrosine kinase inhibitors. His team developed pharmacophores, describing the structural features that are requisites for the binding of synthetic compounds to their respective targets, in order to trigger a biological response. The chemical principles he summarized and published in Science in 1995 have become a key reference for the field of kinase inhibitors.
Dr. Levitzki has received numerous awards throughout his impressive career, among them, The Israel Prize in Biochemistry, the Wolf Prize for Medicine, the Hamilton-Fairley Award from the European Society of Medical Oncology, the Rothschild Prize in Biology, the Nauta Award in Pharmacochemistry from the European Federation for Medicinal Chemistry, as well as two Research Awards from the Prostate Cancer Foundation.
Dr. Levitzki received his doctorate in Biophysics from the Weizmann Institute of Science in Rehovoth and the Hebrew University of Jerusalem, Israel. He completed a postdoctoral fellowship in the department of biochemistry at the University of California, Berkeley with the late Daniel E. Koshland, Jr.